

RealRate

PHARMACEUTICAL 2022

Jazz Pharmaceuticals plc Rank 21 of 466









PHARMACEUTICAL 2022



RealRate

Jazz Pharmaceuticals plc Rank 21 of 466

The relative strengths and weaknesses of Jazz Pharmaceuticals plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Jazz Pharmaceuticals plc compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 87% points. The greatest weakness of Jazz Pharmaceuticals plc is the variable Assets, Current, reducing the Economic Capital Ratio by 14% points.

The company's Economic Capital Ratio, given in the ranking table, is 294%, being 217% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	2,611,334
Cost of Goods Sold	0
Intangible Assets	8,979,937
Liabilities, Current	809,303
Liabilities, Non-Current	0
Other Assets	707,368
Other Compr. Net Income	-266,008
Other Expenses	1,182,645
Other Liabilities	0
Other Net Income	-283,830
Other Revenues	3,094,238
Property and Equipment	0
Research and Development	505,748
Selling, General and Administrative Expense	1,451,683

Output Variable	Value in 1000 USD
Assets	12,298,639
Liabilities	809,303
Expenses	3,140,076
Revenues	3,094,238
Stockholders Equity	11,489,336
Net Income	-329,668
Comprehensive Net Income	-462,672
Economic Capital Ratio	294%

